To investigate the impact of continuous vs intermittent nasogastric feeding during 7 days of bed-rest on peripheral insulin sensitivity, muscle mass, muscle protein synthesis, and mitochondrial function in healthy, young men.
ID
Source
Brief title
Condition
- Glucose metabolism disorders (incl diabetes mellitus)
- Glucose metabolism disorders (incl diabetes mellitus)
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Peripheral insulin sensitivity (measured as glucose infusion rate, GIR)
Secondary outcome
Quadriceps cross-sectional area (CSA), whole body lean mass, leg lean mass,
mitochondrial function, accumulated (7-day) free-living and bed-rested
myofibrillar and mitochondrial fractional synthesis rates, nitrogen balance.
Background summary
Patients admitted to the hospital often undergo a period of bed-rest. This
state of whole-body disuse quickly leads to patients experiencing a substantial
loss of muscle mass and strength, the development of insulin resistance.
Patients often depend on continuous or intermittent enteral nutrition. Work in
animals has revealed that dietary feeding pattern modulates the development of
insulin resistance, such that continuous feeding resulted in greater declines
in insulin sensitivity when compared with bolus feeding. However, the impact of
feeding pattern has not been assessed in humans. One of the factors implicated
in both skeletal muscle loss and insulin resistance is mitochondrial
(dys)function. As postprandial peaks in plasma insulin are likely instrumental
in maintaining mitochondrial function, it could be speculated continuous
feeding would exacerbate bed-rest-induced insulin resistance. However, this is
currently uninvestigated.
Study objective
To investigate the impact of continuous vs intermittent nasogastric feeding
during 7 days of bed-rest on peripheral insulin sensitivity, muscle mass,
muscle protein synthesis, and mitochondrial function in healthy, young men.
Study design
Randomized, parallel (two groups) study design.
Intervention
7 days of bed-rest with continuous or intermittent nasogastric feeding.
Study burden and risks
The risks involved in participating in this experiment are minimal. Three
muscle biopsies will be taken through a small (5 mm) incision, following local
anaesthetics of the skin and muscle fascia, and will heal completely. Multiple
venipunctures will be taken and 4 intravenous catheters will be placed, which
could result in a hematoma. Seven days of bed-rest will impair subject*s
mobility for this period but they will be monitored constantly by researchers.
During the bed-rest, the nasogastric tube can cause some discomfort. The
expected loss of muscle mass and strength following bed-rest will be rapidly
(<4 weeks) regained due to the inclusion of young, healthy volunteers.
Isotopically-labelled water (deuterium oxide or *heavy water*) ingestion has
been previously used in numerous published studies and is entirely safe and
non-toxic when body water enrichments are below approximately 20 mol%.
Universiteitssingel 50 room 2.306
Maastricht 6229 ER
NL
Universiteitssingel 50 room 2.306
Maastricht 6229 ER
NL
Listed location countries
Age
Inclusion criteria
* Male
* Aged from 18-35 years
* 18.5 < BMI < 30 kg·m2
* Recreationally active (performing non-competitive physical exercise at least one time per week for minimally 60 minutes)
Exclusion criteria
* Smoking
* Performing regular resistance training (3+ times per week, carrying out progressive training) in the previous 6 months
* Hypertension (according to WHO criteria) [16] and/or cardiovascular disease
* Any back/leg/knee/neck/postural complaints
* Type 2 diabetes mellitus
* Any family history of thrombosis
* All co-morbidities interacting with mobility and muscle metabolism of the lower limbs
* (e.g. arthritis, spasticity/rigidity, all neurological disorders and paralysis).
* Myocardial infarction within the last 3 years
* Use of certain anti-coagulants (use of thrombocyte aggregation inhibitors such as Ascal, acetylsalicylic acid, aspirin and carbasalaatcalcium is permitted. Use of other thrombocyte aggregation inhibitors will be discussed with the responsible physician)
* A history of deep vein thrombosis (DVT) in the leg
* Having donated blood in the 3 months prior to the study
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL54264.068.15 |